Catalent, Inc. (NYSE: CTLT), the leading global provider of
advanced delivery technologies, development, and manufacturing
solutions for drugs, biologics, cell and gene therapies, and
consumer health products, announced that, effective July 1, 2021,
97% of its electricity usage across its global network is being
procured from renewable energy sources such as wind, solar,
hydroelectric, and biomass. Catalent will purchase renewable energy
certificates for all of its sites operating in North America, South
America and Europe, as well as the majority of its Asia-based
facilities.
Catalent also recently signed a letter of commitment with the
Science-Based Target initiative (SBTi), joining a growing list of
companies setting actionable, science-based, greenhouse gas
emission reduction targets to limit global warming. This commitment
will include calculating and reducing direct and indirect emissions
as the Company continues to evolve and grow.
“As a leader in the growing CDMO industry, we need to
demonstrate our shared commitment, sense of urgency, and value in
contributing to the responsibility and long-term sustainability of
the entire biopharma sector. Sourcing the majority of our
electricity from renewable sources will contribute to our overall
greenhouse gas reduction efforts, which is a significant milestone
towards doing our part and meeting our science-based target
commitment, and I could not be prouder of Catalent’s progress over
the last several years in terms of our environment, social and
governance strategy,” said John Chiminski, Chair and Chief
Executive Officer at Catalent.
To learn more about Catalent’s full Environment, Social and
Governance (ESG) strategy, download the most recent Report at
https://www.catalent.com/about-us/corporate-responsibility/ or
request further information at
corporateresponsibility@catalent.com.
Notes for Editors
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the
leading global provider of advanced delivery technologies,
development, and manufacturing solutions for drugs, biologics, cell
and gene therapies, and consumer health products. With over 85
years serving the industry, Catalent has proven expertise in
bringing more customer products to market faster, enhancing product
performance and ensuring reliable global clinical and commercial
product supply. Catalent employs approximately 15,000 people,
including around 2,400 scientists and technicians, at more than 45
facilities, and in fiscal year 2020 generated over $3 billion in
annual revenue. Catalent is headquartered in Somerset, New Jersey.
For more information, visit www.catalent.com.
MORE PRODUCTS. BETTER TREATMENTS. RELIABLY SUPPLIED.™
FORWARD-LOOKING STATEMENTS
This release contains both historical and forward-looking
statements. All statements other than statements of historical
fact, are, or may be deemed to be, forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements generally can be
identified by the use of statements that include phrases such as
“believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,”
“project,” “foresee,” “likely,” “may,” “will,” “would,” or other
words or phrases with similar meanings. Similarly, statements that
describe Catalent’s objectives, plans, or goals are, or may be,
forward-looking statements, including statements concerning
Catalent’s commitments to rely on renewable energy and its
commitments to calculating and implementing science-based targets
for GHG emissions. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual
results could vary materially from Catalent’s expectations and
projections. Some of the factors that could cause actual results to
differ include, but are not limited to, the following: the current
or future effects of the COVID-19 pandemic on Catalent’s and its
clients’ businesses; participation in a highly competitive market
and increased competition that may adversely affect Catalent’s
business; demand for its offerings, which depends in part on its
customers’ research and development and the clinical and market
success of their products; product and other liability risks that
could adversely affect Catalent’s results of operations, financial
condition, liquidity and cash flows; failure to comply with
existing and future regulatory requirements; failure to provide
quality offerings to customers could have an adverse effect on
Catalent’s business and subject it to regulatory actions and costly
litigation; problems providing the highly exacting and complex
services or support required; global economic, political and
regulatory risks to Catalent’s operations; inability to enhance
existing or introduce new technology or service offerings in a
timely manner; inadequate patents, copyrights, trademarks and other
forms of intellectual property protections; fluctuations in the
costs, availability, and suitability of the components of the
products Catalent manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials;
changes in market access or healthcare reimbursement in the United
States or internationally; fluctuations in the exchange rate of the
U.S. dollar against other currencies, including as a result of the
U.K.’s exit from the European Union; adverse tax legislative or
regulatory initiatives or challenges or adjustments to Catalent’s
tax positions; loss of key personnel; risks generally associated
with information systems; inability to complete any future
acquisitions or other transactions that may complement or expand
its business or divest of non-strategic businesses or assets and
difficulties in successfully integrating acquired businesses and
realizing anticipated benefits of such acquisitions; risks
associated with timely and successfully completing, and correctly
anticipating the future demand predicted for, capital expansion
projects at existing facilities, offerings and customers’ products
that may infringe on the intellectual property rights of third
parties; environmental, health and safety laws and regulations,
which could increase costs and restrict operations; labor and
employment laws and regulations or labor difficulties, which could
increase costs or result in operational disruptions; additional
cash contributions required to fund Catalent’s existing pension
plans; substantial leverage that may limit its ability to raise
additional capital to fund operations and react to changes in the
economy or in the industry; exposure to interest-rate risk to the
extent of its variable-rate debt preventing it from meeting its
obligations under its indebtedness; the availability of renewable
energy in quantities and at prices that are economically feasible
for Catalent; and changes to environmental standards, guidance, or
related technological capabilities that may render it more
expensive or more difficult to reach environmental goals. For a
more detailed discussion of these and other factors, see the
information under the caption “Risk Factors” in Catalent’s Annual
Report on Form 10-K for the fiscal year ended June 30, 2020, filed
August 31, 2020. All forward-looking statements speak only as of
the date of this release or as of the date they are made, and
Catalent does not undertake to update any forward-looking statement
as a result of new information or future events or developments
except to the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210803005081/en/
Media Contacts:
Chris Halling +44 (0)7580 041073 chris.halling@catalent.com
Richard Kerns +44 (0) 161 728 5880 richard@nepr.agency
Investor Contact:
Paul Surdez +1 (732) 537-6325 investors@catalent.com
Catalent (NYSE:CTLT)
過去 株価チャート
から 6 2024 まで 7 2024
Catalent (NYSE:CTLT)
過去 株価チャート
から 7 2023 まで 7 2024